Select up to 3 products
LTB3 is the LTA hydrolase metabolite of LTA3 in the leukotriene biosynthetic pathway. LTB3 and LTB4 are equipotent in their pro-inflammatory effects. However, LTB3 is five times less potent than LTB4 in eliciting chemotaxis of human neutrophils.
Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .DELTA.5/.DELTA.6 desaturase. Mice injected with CP 24,879 at 3 mg/kg had a reduction of...
CREB (cAMP-response-element-binding protein) is a transcription factor that binds to cAMP-responsive element (CRE) promoter sites to regulate the transcription of numerous genes involved in metabolic regulation, depression, long term memory, and other physiological processes. Phosphorylation on...
A dihydropyridine used as an antihypertensive agent due to its ability to block L-type and T-type calcium channels; also binds to adenosine A1, A2A, and A3 receptors with Ki values of 8.96, 23.0, and 8.3 µM, respectively.
An internal standard for the quantification of SAH by GC- or LC-MS.
A highly potent inhibitor of p38 MAPK (Kd = 0.1 nM) that blocks TNFα release in LPS-stimulated THP-1 cells with an IC50 value of 18 nM; At 10 μM, inhibits JNK2α2 in vitro.
A polyketide that serves as a precursor for many different antibiotic and anticancer agents.
An essential cofactor functioning as an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism; the pantothenate kinase step of the coenzyme A biosynthetic pathway has been identified as a target for the development of antibacterial compounds.
A compound that has been used to investigate the relationship between intramolecular rotational dynamics and molecular and crystal structure using NMR spin-lattice relaxation experiments.
A widely-used non-specific inhibitor of cAMP and cGMP PDEs (IC50 = 19, 50, 18, 13, 32, 7, and 50 μM for PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, and PDE11, respectively).
A creatine analog that alters skeletal muscle energy expenditure; reduces cellular ATP, creatine, and phosphocreatine levels and stimulates AMPK, activating PGC-1α; increases the expression of genes for oxidative phosphorylation, electron transport chain, and mitochondrial biogenesis.
A second generation cephalosporin antibiotic that has been used to treat a wide range of gram-negative and gram-positive bacteria including anaerobes.
A saturated fatty acyl ethanolamide devoid of classical (CB1/CB2) activity; does not bind to the murine CB1 receptor and does not compete with AEA as a substrate for FAAH; a non-CB receptor-mediated pharmacology is still being elucidated.
A substrate for cPLA2.
Source: Recombinant N-terminal GST-tagged protein expressed in E. coli Mr: 42.6 kDa This product contains the tudor domain of TP53BP1. Binding of TP53BP1 to dimethylated lysine 382 on p53 (p53 K382me2), as well as histone H4K20me2, through the tudor domain, has been shown to be important for TP53BP1...
Ins(1,2,6)-P3 is a member of the inositol phosphate (InsP) family of second messengers that play a critical role in the transmission of cellular signals. The most studied InsP, Ins(1,4,5)-P3 is a second messenger produced in cells by PLC-mediated hydrolysis of PtdIns-4,5-biphosphate. Binding of...
An inhibitor of lysosomal exocytosis.
A time-dependent, dual inhibitor of 5α-reductase (apparent Kis = 17 and 4.3 nM at 10 and 30 minute reaction times, respectively) that is frequently used in the treatment of benign prostatic hyperplasia.
An intermediate used in the synthesis of potent DP2 receptor antagonists.
An inactive analog of the PLC activator m-3M3FBS that can be used as a negative control.
A 4-azasteroid analog of testosterone that competitively blocks type II 5α-reductase activity (IC50 = 4.2 nM) with 100-fold greater affinity than for the type I enzyme; used in the treatment of benign prostatic hyperplasia, decreasing human prostatic dihydrotestosterone levels by...
A stable inhibitor of FAS that leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.
A PAR4 antagonist (IC50 = 140 nM) that exhibits 71-fold selectivity for PAR4 over PAR1 (IC50 = 10 μM) in isolated human platelets.
A powerful effector in both the TetR and revTetR transcriptional regulator systems, binding the Tet repressor 35-fold more strongly than Tet; does not act a general inhibitor of translation and is a poor antibiotic.